logo
Share SHARE
FONT-SIZE Plus   Neg

Aduro BioTech Acquires GVAX Assets From BioSante Pharma - Quick Facts

Aduro BioTech Inc. announced the acquisition of all GVAX assets from BioSante Pharmaceuticals Inc. (BPAX), including intellectual property and cell lines.

Aduro previously licensed two GVAX vaccines, GVAX Pancreas and GVAX Prostate, for use in combination with its Listeria-based vaccines.

Aduro said that the new acquisition covers all uses and includes additional vaccines for multiple myeloma and breast and colon cancer and assumes rights to the existing license agreement for GVAX Melanoma.

Under its purchase agreement with BioSante, Aduro paid $1 million upfront and has committed to additional milestone and royalty payments after commercialization of GVAX product(s).

GVAX vaccines are based on human cancer cell lines that are genetically modified to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune-stimulatory cytokine.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Dell Inc. decided to end its Venue brand Android tablets and will focus on Windows 10 2-in-1 devices. There will be no operating system upgrades for Venue, however it will continue active warranty and service contract. Tech giant Apple Inc. has developed a new technology that will prohibit audiences using their iPhones to record concerts. The Cupertino, California-based company has secured a patent in the US for its new technology. The technology uses infrared signals to shut down cameras on audience members' smartphones. The... Snacks giant Mondelez International Inc. (MDLZ) made a takeover bid of $23 billion to acquire chocolate behemoth Hershey Co. (HSY) that would create the world's largest chocolate company. Nevertheless, shares of Hershey jumped over 15 percent after the company revealed that it has rejected the offer. "The...
comments powered by Disqus
Follow RTT